Citations

Clear

426 citation(s) found for "ST, Reza".

Survival, Tumor Control, and Safety Outcomes of Proton Therapy in Sinonasal Cancer Population: A Systematic Review and Meta‐Analysis
Vasudevan, Srivatsa Surya , Sharifi, Ahmad Reza , Patel, Samir H. , Holtzman, Adam L. , Mohammadi, Homan , Donaldson, Angela M. , Candelo, Estephanía , Sharifi, Alireza , Holtzman, Adam , Daniel, J. , Routman, David M.

Mayo Clinic

Head & Neck | January 24, 2025 | Volume: 47 | Issue: 4 | Pages: 1291-1305

10.1002/hed.28082 | PMID 39853705 Get It

ABSTRACTBackgroundIn sinonasal cancer (SNC), treatment with proton therapy (PT) provides excellent local control, especially after gross total resection. Because of the heterogeneity and rarity of this disease site, a comprehensive assessment of toxicity, survival, and control rates is lacking. Our primary objective was to assess the toxicity outcomes of PT in SNC patients, with a secondary aim of assessing survival and tumor control after PT.MethodsPubMed, Embase, EBSCO, Scopus, Science Direct, Web of Science, Ovid, Proquest, and Cochrane Library were searched from inception to August 2024 reporting PT acute and late toxicity, survival, and tumor control outcomes in SNC patients. A random‐effect meta‐analysis was used to assess the pooled safety, survival, and tumor control outcomes. The primary analysis was to report acute and late toxicity. The secondary aims included overall survival (OS), disease‐free survival (DFS), local control (LC), regional control (RC), and distant metastasis control (DMC) rate.ResultsFourteen studies were included for qualitative analysis. We pooled data from 756 patients who received PT for SNC. Among acute toxicity (AT), there was a 31.9% occurrence rate of grade ≥ 3 events, whereas within late toxicity (LT), grade ≥ 3 events occurred at a rate of 35.3%. Most LT (62.1%) were classified as grade 2, with the most frequent being ocular (24.8%) or neurological (18.4%) toxicities. The most common grade ≥ 3 toxicities were mucositis (15.3%) in AT and ocular toxicity (9.6%) in LT. The pooled 5‐year OS, DFS, LC, RC, and DMC were 36.8%, 34.2%, 35.6%, 28.6%, and 54.3%, respectively.ConclusionOur analysis demonstrates that PT‐treated SNC patients experience acceptable rates of acute and LT consistent with other published outcomes with highly conformal radiation techniques. PT demonstrates favorable OS and DFS. Further prospective and comparative effectiveness research is needed to better quantify the magnitude of the benefit of PT or other forms of radiation modalities.
Interaction Between Lipoprotein(a) and Other Lipid Molecules: A Review of the Current Literature
Sheashaa, Hesham, Mousa, Hana, Abbas, Mohammed Tiseer , Farina, Juan M. , Pereyra, Milagros , Scalia, Isabel G. , Ali, Nima Baba , Javadi, Niloofar , Bismee, Nadera N. , Esfahani, Sogol Attaripour , Ibrahim, Omar , Abdelfattah, Fatmaelzahraa , Abdelnabi, Mahmoud , Arsanjani, Reza , Sheashaa, Hesham , Pereyra, Milagros , Scalia, Isabel G , Baba Ali, Nima , Ibrahim, Omar H , Abdelfattah, Fatmaelzahraa , Arsanjani, Reza , Farina, Juan M , Abbas, Mohammed Tiseer , Awad, Kamal , Ibrahim, Ramzi

Mayo Clinic

Biomolecules | January 22, 2025 | Volume: 15 | Issue: 2 | Pages: 162

10.3390/biom15020162 | PMID 40001465 Get It

Lipoprotein(a) [Lp(a)] is a well-established causal risk factor for cardiovascular diseases (CVDs), as reported by multiple Mendelian randomization studies and large epidemiological studies. When elevated Lp(a) is combined with other risk factors, most notably elevated low-density lipoprotein cholesterol (LDL-C), a synergistic atherogenic effect has been reported. However, the current literature is conflicting regarding how Lp(a) interacts in the context of controlled LDL-C levels (e.g., <70 mg/dL) and whether reducing LDL-C can modify the atherogenic effect of Lp(a). In some studies, elevated Lp(a) was still significantly associated with a higher risk of cardiovascular events, despite controlled levels of LDL-C. In contrast, multiple studies have reported attenuation of the cardiovascular risk mediated by elevated Lp(a) with lower LDL-C levels. Moreover, the relationship between Lp(a) and triglycerides, high-density lipoprotein, and very low-density lipoprotein remains unclear. In this literature review, we summarize and discuss the current evidence regarding the interactions between Lp(a) and other lipid molecules, how they contribute to the pathogenesis of CVD, and future perspectives, particularly in the current era where promising targeted Lp(a)-lowering therapies are under development.
Unmasking Racial, Ethnic, and Socioeconomic Disparities in United States Chordoma Clinical Trials: Systematic Review
Bangash, Ali Haider , Ryvlin, Jessica , Chakravarthy, Vikram , Sullivan, Patricia L. Zadnik, Niu, Tianyi , Galgano, Michael , Shin, John H., Gokaslan, Ziya L. , Fourman, Mitchell S. , Gelfand, Yaroslav , Murthy, Saikiran G. , Yassari, Reza , Galgano, Michael A , Fourman, Mitchell S , De la Garza Ramos, Rafael , Bangash, Ali Haider , Akinduro, Oluwaseun O. , Sullivan, Patricia Zadnik , Ramos, Rafael De la Garza

Mayo Clinic

Cancers | January 13, 2025 | Volume: 17 | Issue: 2 | Pages: 225

10.3390/cancers17020225 | PMID 39858008 Get It

Background: Chordoma is a rare bone cancer with limited treatment options. Clinical trials are crucial for developing effective therapies, but their success depends on including diverse patient populations. The objective of this study was to systematically evaluate the reporting of racial, ethnic, and socioeconomic diversity in United States clinical trials exploring treatment for chordoma. Methods: A literature search was conducted through PubMed/Medline, Cochrane, Epistemonikos, and ClinicalTrials.gov databases for published US chordoma trials up until 19 August 2024. The data collected included trial characteristics and racial and ethnic data, as well as socioeconomic indicators when available. Methodological Index for Non-Randomized Studies (MINORS) and Revised Cochrane Risk-of-Bias Tool for Randomized Trials (RoB2) analyses were adopted to assess the methodological quality. The N-1 Chi-squared (χ2) test was implemented to compare the reported racial and ethnic data with the most recent US Census Bureau data. Results: Five trials involving 111 patients (median age: 63 years; 34% female) were included. Four studies (80%) were single-arm non-randomized studies with one study (25%) having a high methodological quality and three (75%) having a moderate quality based on the MINORS analysis. Most patients (91%, n = 82) were White/Caucasian, representing a proportion which was significantly higher than the reported 75% in the US population (p = 0.0005). Black/African American patients (2%, n = 2) were significantly underrepresented compared to the 14% in the US population (p = 0.0015). Regarding ethnicity, Hispanic/Latino patients (7%, n = 6) were significantly underrepresented compared to the 20% in the US population (p = 0.0021). No measures of socioeconomic status were reported. Conclusions: This systematic review highlighted the need for improved racial and ethnic diversity in chordoma trials and the better reporting of socioeconomic data. The underrepresentation of minority groups may obscure potential disparities in disease incidence, treatment access, and clinical outcomes.
A Comprehensive Review of Artificial Intelligence (AI) Applications in Pulmonary Hypertension (PH)
Esfahani, Sogol Attaripour , Ali, Nima Baba , Farina, Juan M. , Scalia, Isabel G. , Pereyra, Milagros , Abbas, Mohammed Tiseer , Javadi, Niloofar , Bismee, Nadera N. , Abdelfattah, Fatmaelzahraa E., Ibrahim, Omar , Sheashaa, Hesham, Barry, Timothy , Scott, Robert L. , Ayoub, Chadi , Arsanjani, Reza , Attaripour Esfahani, Sogol, Baba Ali, Nima , Awad, Kamal , Ibrahim, Omar H , Sheashaa, Hesham , Barry, Timothy , Arsanjani, Reza , Farina, Juan M , Pereyra, Milagros , Scalia, Isabel G , Abbas, Mohammed Tiseer , Abdelfattah, Fatmaelzahraa , Awad, Kamal

Mayo Clinic

Medicina | January 7, 2025 | Volume: 61 | Issue: 1 | Pages: 85

10.3390/medicina61010085 | PMID 39859065 Get It

Background: Pulmonary hypertension (PH) is a complex condition associated with significant morbidity and mortality. Traditional diagnostic and management approaches for PH often face limitations, leading to delays in diagnosis and potentially suboptimal treatment outcomes. Artificial intelligence (AI), encompassing machine learning (ML) and deep learning (DL) offers a transformative approach to PH care. Materials and Methods: We systematically searched PubMed, Scopus, and Web of Science for original studies on AI applications in PH, using predefined keywords. Out of more than 500 initial articles, 45 relevant studies were selected. Risk of bias was evaluated using PROBAST (Prediction model Risk of Bias Assessment Tool). Results: This review examines the potential applications of AI in PH, focusing on its role in enhancing diagnosis, disease classification, and prognostication. We discuss how AI-powered analysis of medical data can improve the accuracy and efficiency of detecting PH. Furthermore, we explore the potential of AI in risk stratification, leading to treatment optimization for PH. Conclusions: While acknowledging the existing challenges and limitations and the need for continued exploration and refinement of AI-driven tools, this review highlights the significant promise of AI in revolutionizing PH management to improve patient outcomes.
An international Delphi consensus on patient preparation for metabolic and bariatric surgery
Clyde, Danielle , Adib, Reza, Baig, Sarfaraz Jalil , Bhasker, Aparna Govil , Catalain, Copaescu, Clare, Ken , Beaux, Andrew de, Drummond, Gillian, Fawal, Hayssam, Ghanem, Omar M. , Hopkins, George, Kothari, Shanu N. , Kow, Lilian , Faria, Sílvia Leite , Madhok, Brij, Mahon, David, Miller, Karl , Nimeri, Abdelrahman , O’Kane, Mary , Poggi, Luis , Saliminen, Paulina, Sarkar, Rupa , Shenfine, Jon, Sogg, Stephanie , Suter, Michel , Taha, Safwan , Tahrani, Abd A. , Voon, Kelvin , Welbourn, Richard , Lamb, Peter , Mahawar, Kamal , Yang, Wah , Salminen, Paulina , Kermansaravi, Mohammad , Zerrweck, Carlos , Yang, Wah , Byrne, James Patrick , Cameron, David, Fried, Martin , Graham, Yitka N. H. , Goel, Ramen , Husain, Farah Anwari , Joyce, Brian, Miras, Alexander Dimitri , Moussa, Osama , Neto, Manoel Galvão , Parmar, Chetan D. , Peterli, Ralph , Stenberg, Erik , Vilallonga, Ramón , Robertson, Andrew G.

Mayo Clinic

Clinical Obesity | December 14, 2024 | Volume: 15 | Issue: 2 | Pages: No page available

10.1111/cob.12722 | PMID 39673462 Get It

SummaryGlobal obesity rates have risen dramatically, now exceeding deaths from starvation. Metabolic and bariatric surgery (MBS), initially for severe obesity (BMI ≥35 kg/m2), is performed globally over 500 000 times annually, offering significant metabolic benefits beyond weight loss. However, varying eligibility criteria globally impact patient care and healthcare resources. Updated in 2022, ASMBS and IFSO guidelines aim to standardise MBS indications, reflecting current understanding and emphasising comprehensive preoperative assessments. Yet, clinical variability persists, necessitating consensus‐based recommendations. This modified Delphi study engaged 45 global experts to establish consensus on perioperative management in MBS. Experts selected from bariatric societies possessed expertise in MBS and participated in a two‐round Delphi protocol. Consensus was achieved on 90 of 169 statements (53.3%), encompassing multidisciplinary team composition, patient selection criteria, preoperative testing, and referral pathways. The agreement highlighted the critical role of comprehensive preoperative assessments and the integration of healthcare professionals in MBS. These findings offer essential insights to standardise perioperative practices and advocate for evidence‐based guidelines in MBS globally. The study underscores the need for unified protocols to optimise outcomes and guide future research in MBS.
Bioprosthetic Aortic Valve Degeneration After TAVR and SAVR: Incidence, Diagnosis, Predictors, and Management
Bismee, Nadera N. , Javadi, Niloofar , Khedr, Ahmed E. , Omar, Fatma, Awad, Kamal , Abbas, Mohammed Tiseer , Scalia, Isabel G. , Pereyra, Milagros , Bcharah, George , Farina, Juan M. , Arsanjani, Reza , Khedr, Ahmed , Arsanjani, Reza , Farina, Juan M , Pereyra, Milagros , Scalia, Isabel G , Abbas, Mohammed Tiseer , Awad, Kamal , Omar, Fatma, Sell‐Dottin, Kristen

Mayo Clinic

Journal of Cardiovascular Development and Disease | December 2, 2024 | Volume: 11 | Issue: 12 | Pages: 384

10.3390/jcdd11120384 | PMID 39728274 Get It

Bioprosthetic aortic valve degeneration (BAVD) is a significant clinical concern following both transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR). The increasing use of bioprosthetic valves in aortic valve replacement in younger patients and the subsequent rise in cases of BAVD are acknowledged in this review which aims to provide a comprehensive overview of the incidence, diagnosis, predictors, and management of BAVD. Based on a thorough review of the existing literature, this article provides an updated overview of the biological mechanisms underlying valve degeneration, including calcification, structural deterioration, and inflammatory processes and addresses the various risk factors contributing to BAVD, such as patient demographics, comorbidities, and procedural variables. The difficulties in early detection and accurate diagnosis of BAVD are discussed with an emphasis on the need for improved imaging techniques. The incidence and progression of BAVD in patients undergoing TAVR versus SAVR are compared, providing insights into the differences and similarities between the two procedures and procedural impacts on valve longevity. The current strategies for managing BAVD, including re-intervention options of redo surgery and valve-in-valve TAVR, along with emerging treatments are discussed. The controversies in the existing literature are highlighted to offer directions for future investigations to enhance the understanding and management of BAVD.
Evaluating large language models in echocardiography reporting: opportunities and challenges
Chao, Chieh-Ju, Banerjee, Imon , Arsanjani, Reza , Ayoub, Chadi , Tseng, Andrew S. , Delbrouck, Jean-Benoit, Kane, Garvan C. , López-Jiménez, Francisco , Oh, Jae K. , Fei-Fei, Li , Adeli, Ehsan, Tseng, A S , Erickson, Bradley, Banerjee, Imon , Lopez-Jimenez, Francisco , Arsanjani, Reza , Chao, Chieh‐Ju , Attia, Zachi I. , Erickson, Bradley J. , Adeli, Ehsan , Langlotz, Curtis P.

Mayo Clinic

European Heart Journal - Digital Health | November 27, 2024 | Volume: 6 | Issue: 3 | Pages: 326-339

10.1093/ehjdh/ztae086 | PMID 40395412 Get It

Abstract Aims The increasing need for diagnostic echocardiography tests presents challenges in preserving the quality and promptness of reports. While Large Language Models (LLMs) have proven effective in summarizing clinical texts, their application in echo remains underexplored. Methods and results Adult echocardiography studies, conducted at the Mayo Clinic from 1 January 2017 to 31 December 2017, were categorized into two groups: development (all Mayo locations except Arizona) and Arizona validation sets. We adapted open-source LLMs (Llama-2, MedAlpaca, Zephyr, and Flan-T5) using In-Context Learning and Quantized Low-Rank Adaptation fine-tuning (FT) for echo report summarization from ‘Findings’ to ‘Impressions.’ Against cardiologist-generated Impressions, the models’ performance was assessed both quantitatively with automatic metrics and qualitatively by cardiologists. The development dataset included 97 506 reports from 71 717 unique patients, predominantly male (55.4%), with an average age of 64.3 ± 15.8 years. EchoGPT, a fine-tuned Llama-2 model, outperformed other models with win rates ranging from 87% to 99% in various automatic metrics, and produced reports comparable to cardiologists in qualitative review (significantly preferred in conciseness (P &lt; 0.001), with no significant preference in completeness, correctness, and clinical utility). Correlations between automatic and human metrics were fair to modest, with the best being RadGraph F1 scores vs. clinical utility (r = 0.42) and automatic metrics showed insensitivity (0–5% drop) to changes in measurement numbers. Conclusion EchoGPT can generate draft reports for human review and approval, helping to streamline the workflow. However, scalable evaluation approaches dedicated to echo reports remains necessary.
Intracranial hypertension and papilledema secondary to an unruptured arteriovenous malformation: Review of the literature
Griessenauer, Christoph J. , Bahrami, Reza , Mirsardoo, Hojjat, Sahraei, Rana, Mortazavi, Abolghasem , Griessenauer, Christoph J , Wipplinger, Christoph , Mortazavi, Abolghasem , Ghorbani, Mohammad

Mayo Clinic

The Neuroradiology Journal | November 21, 2024 | Volume: 38 | Issue: 4 | Pages: 387-393

10.1177/19714009241303068 | PMID 39572165 Get It

Arteriovenous malformations (AVMs) are abnormal connections of arteries and veins without intermediate capillary components. As such, AVMs can remain asymptomatic or have a variety of clinical presentations ranging from mild headaches to severe symptoms like seizures, hemorrhage, and subsequent coma. Papilledema and increased intracranial pressure without hydrocephalus or hemorrhage are rare forms of presentations of cerebral AVM. The mechanism of intracranial hypertension accompanying brain AVMs is not entirely understood, and the right treatment strategy is controversial. Here, we present the treatment and outcomes of four patients with unruptured AVMs who presented with intracranial hypertension accompanied by visual symptoms, papilledema, and without evidence of hydrocephalus. In cases of AVMs accompanied by intracranial hypertension, AVM treatment should be considered the main target of management.
Controlled low-density lipoprotein cholesterol attenuates cardiovascular risk mediated by elevated lipoprotein(a) after percutaneous coronary intervention
Mahmoud, Ahmed , Awad, Kamal , Ali, Nima Baba , Abdalla, Hesham, Badr, Amro , Elahi, Muhammad Ali , Pereyra, Milagros , Javadi, Niloofar , Bismee, Nadera N. , Lester, Steven J., Arsanjani, Reza, Pereyra, Milagros , Mahmoud, Ahmed K , Awad, Kamal , Farina, Juan M. , Abbas, Mohammed Tiseer , Scalia, Isabel G. , Alsidawi, Said , Arsanjani, Reza

Mayo Clinic

Coronary Artery Disease | November 14, 2024 | Volume: 36 | Issue: 3 | Pages: 183-189

10.1097/mca.0000000000001460 | PMID 39774184 Get It

Background Lipoprotein(a) [Lp(a)] is an independent, causal risk factor for cardiovascular disease. However, it is still unclear whether controlling low-density lipoprotein cholesterol (LDL-C) to optimal levels can attenuate cardiovascular risk mediated by elevated Lp(a), especially in the setting of secondary prevention. Methods Adult patients with a baseline Lp(a) measurement who underwent percutaneous coronary intervention (PCI) and reached their LDL-C target levels (<70 mg/dl) at Mayo Clinic sites between 2006 and 2017 were included. Primary outcomes included major adverse cardiovascular events (MACE) and all-cause mortality. Kaplan–Meier curves were created to compare the survival probabilities among patients with Lp(a) ≥ 50 mg/dl compared with Lp(a) < 50 mg/dl. Multivariable Cox regression analyses were performed to quantify the association of elevated Lp(a) with our relevant outcomes and to control for possible confounders. Results In total, 878 patients (median age: 68 years, and 74% males) who underwent PCI were included for analysis. Of them, 29.7% had elevated Lp(a) ≥ 50 mg/dl. Kaplan–Meier curves did not reveal any significant difference in survival probabilities for elevated Lp(a) for any outcome including MACE (P = 0.91), all-cause mortality (P = 0.26), or the separate MACE components. Similarly, the multivariable analysis showed no significant association for MACE (hazard ratio: 1.07, 95% confidence interval: 0.84–1.37) or all-cause mortality (hazard ratio: 0.98, 95% confidence interval: 0.74–1.30). Conclusion In patients who underwent PCI and have their LDL-C controlled below 70 mg/dl, no significant association was found between elevated Lp(a) ≥ 50 mg/dl and risk for MACE or all-cause mortality.
Abstract 4147498: Prognostic Significance of Echocardiographic Transaortic Flow Rate in Aortic Valve Stenosis: a Systematic Review and Meta-Analysis
Hatamnejad, Mohammad Reza , Mombeini, Hoda , Chichagi, Fatemeh , Arbabi, Mahta, Jamshidi, Parnian , Korani, Setayesh Sotoudehnia , Bandary, Maryam Sahafi, Sotoudehnia, Setayesh , Piroozkhah, Moein

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4147498 Get It

Background: Echocardiographic evaluation of Aortic valve stenosis (AS) severity relies on aortic valve area, peak jet velocity, and mean transaortic gradient. In pursuit of improving accuracy, the transaortic flow rate (FR), defined as the ratio of stroke volume to systolic ejection time, has been introduced. However, its prognostic value in AS patients remains controversial. Aim: This study aims to systematically review the predictive value of FR in AS patients and provide quantitative pooled analysis results where applicable. Methods: A systematic search of PubMed/Medline, Embase, Scopus, Web of Science, and Cochrane was conducted for observational studies on AS patients published up to March 15, 2024. Studies were included if they assessed the clinical prognostic utility of FR with at least three months of follow-up. Pooled estimates and 95% CI for FR's hazard ratio (HR) in each binary outcome were calculated using a random effects model. Results: Nineteen studies with 9456 patients (mean age 75) underwent descriptive analysis, and 17 eligible studies were included in the meta-analysis. For predicting all-cause mortality, the pooled HR for low FR measured at rest (cut-off value 200-210 mL/s) was 1.32 (95% CI: 1.01–1.63, I2: 69%, p<0.05) (Figure 1. A). For FR measured during stress echocardiography, the pooled HR was higher at 1.58 (95% CI: 1.20–1.96, I2: 0%, p<0.05). Additionally, every 100 mL/s increase in FR significantly reduced all-cause mortality; the HR was 0.61 (95% CI: 0.47–0.75, I2: 47%) for FR measured at rest (Figure 1. B), and 0.61 (95% CI: 0.31–0.91, I2: 65%) for FR measured during stress echo. For the combined endpoint of mortality and hospitalization, the HRs were as follows: 2.54 (95% CI: -0.99–6.08, I2: 48%) and 2.57 (95% CI: 0.69–4.44, I2: 0%) for the low FR group at rest and during stress echo, respectively. For every 100 mL/s increase in FR, the HRs were 0.19 (95% CI: -0.19–0.58, I2: 61%) at rest and 0.36 (95% CI: 0.18–0.54, I2: 0%) during stress echo. Conclusion: FR is a prognostic marker for all-cause mortality in AS patients, indicating its potential for risk stratification. Incorporating FR into clinical assessments could help personalize follow-up and monitoring strategies.